论文部分内容阅读
心房颤动(简称房颤)患者具有更高的卒中风险。左心耳被证实是房颤患者血栓形成的主要部位。经皮左心耳封堵术是近年来发展的通过微创导管术封堵左心耳以达到预防房颤患者血栓栓塞的新技术。许多左心耳封堵器已经正式上市或者进入临床研究阶段。Watchman是当前使用最广、循证医学证据最多的封堵器。Protect-AF研究是第一个头对头对比华法林预防卒中的随机对照研究。目前,Watchman成为目前第一个经过美国FDA批准的左心耳封堵器。与此同时,国产左心耳封堵器LAmbre及Lefort也崭露头角并相继进入临床研究。左心耳封堵术开启了全球预防房颤患者卒中治疗的新模式,即由“局部封堵、单次手术”替代传统的“全身抗凝、终生服药”。
Patients with atrial fibrillation (atrial fibrillation) have a higher risk of stroke. Left atrial appendage proved to be the main site of thrombosis in patients with atrial fibrillation. Percutaneous left atrial appendage occlusion is a new technique that has been developed in recent years to block the left atrial appendage by minimally invasive catheterization in order to prevent thromboembolism in patients with atrial fibrillation. Many left atrial appendage occluders have been officially listed or entered the clinical research stage. Watchman is currently the most widely used, evidence-based evidence-based occluder. The Protect-AF study was the first RCT to be a head-to-head comparison of warfarin prophylaxis. Currently, Watchman is the first left atrial appendage occluder approved by the U.S. FDA. At the same time, domestic left atrial appendage occluder LAmbre and Lefort also emerge and have entered clinical research. Left atrial appendage occlusion opens a new global model of stroke prevention in patients with atrial fibrillation, replacing traditional “systemic anticoagulation and lifelong medication” with “partial occlusion and single surgery.”